CN112533600A - 用于治疗小细胞肺癌的喹啉衍生物 - Google Patents

用于治疗小细胞肺癌的喹啉衍生物 Download PDF

Info

Publication number
CN112533600A
CN112533600A CN201980052510.4A CN201980052510A CN112533600A CN 112533600 A CN112533600 A CN 112533600A CN 201980052510 A CN201980052510 A CN 201980052510A CN 112533600 A CN112533600 A CN 112533600A
Authority
CN
China
Prior art keywords
acid
lung cancer
small cell
cell lung
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980052510.4A
Other languages
English (en)
Other versions
CN112533600B (zh
Inventor
王善春
于鼎
王训强
彭邦安
刘璐
代洁
周航
缪亚东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202311015937.1A priority Critical patent/CN117085016A/zh
Priority to CN202311015952.6A priority patent/CN117085017A/zh
Publication of CN112533600A publication Critical patent/CN112533600A/zh
Application granted granted Critical
Publication of CN112533600B publication Critical patent/CN112533600B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

本申请属于医药领域，提供一种用于治疗小细胞肺癌的喹啉衍生物。本申请所提供的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐，可用于治疗小细胞肺癌，尤其是对于难治性复发的小细胞肺癌患者，能显著地延长其生存期，对于脑转移性小细胞肺癌的疗效也非常显著。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980052510.4A 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物 Active CN112533600B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311015937.1A CN117085016A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物
CN202311015952.6A CN117085017A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110880896 2018-09-18
CN201811088089 2018-09-18
PCT/CN2019/106406 WO2020057539A1 (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311015952.6A Division CN117085017A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物
CN202311015937.1A Division CN117085016A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物

Publications (2)

Publication Number Publication Date
CN112533600A true CN112533600A (zh) 2021-03-19
CN112533600B CN112533600B (zh) 2023-07-14

Family

ID=69888373

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311015937.1A Pending CN117085016A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物
CN202311015952.6A Pending CN117085017A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物
CN201980052510.4A Active CN112533600B (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202311015937.1A Pending CN117085016A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物
CN202311015952.6A Pending CN117085017A (zh) 2018-09-18 2019-09-18 用于治疗小细胞肺癌的喹啉衍生物

Country Status (7)

Country Link
US (1) US20220031689A1 (zh)
EP (1) EP3854396A4 (zh)
CN (3) CN117085016A (zh)
AU (1) AU2019344764A1 (zh)
CA (1) CA3112946A1 (zh)
SG (1) SG11202102682SA (zh)
WO (1) WO2020057539A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
CN103664892B (zh) 2010-08-01 2015-09-02 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN114767680A (zh) * 2014-12-09 2022-07-22 正大天晴药业集团股份有限公司 治疗非小细胞肺癌的喹啉衍生物
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)", 《CLINICALTRIALS.GOV》 *

Also Published As

Publication number Publication date
CA3112946A1 (en) 2020-03-26
WO2020057539A1 (zh) 2020-03-26
CN117085016A (zh) 2023-11-21
AU2019344764A1 (en) 2021-05-20
EP3854396A1 (en) 2021-07-28
US20220031689A1 (en) 2022-02-03
EP3854396A4 (en) 2022-06-29
CN117085017A (zh) 2023-11-21
CN112533600B (zh) 2023-07-14
SG11202102682SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
AU2015360095B2 (en) Quinoline derivative against non-small cell lung cancer
WO2018214925A1 (zh) 用于治疗结直肠癌的喹啉衍生物
WO2017177962A1 (zh) 一种用于治疗胃癌的喹啉衍生物
AU2018380174A1 (en) Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
WO2016091165A1 (zh) 治疗非小细胞肺癌的喹啉衍生物
WO2020211860A1 (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
CN112638385B (zh) 用于治疗脑肿瘤的喹啉衍生物
WO2017118401A1 (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
CN111757737B (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
WO2021219137A1 (zh) 用于治疗met基因异常疾病的氨基吡啶衍生物
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046131

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant